You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Updates on cardiovascular outcome trials in diabetes
|
|---|---|
| Published in |
Cardiovascular Diabetology, October 2017
|
| DOI | 10.1186/s12933-017-0610-y |
| Pubmed ID | |
| Authors |
Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello, on behalf of the D&CVD EASD Study Group |
| Abstract |
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 25% |
| Japan | 1 | 13% |
| Unknown | 5 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 120 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 17% |
| Student > Master | 18 | 15% |
| Student > Bachelor | 12 | 10% |
| Other | 11 | 9% |
| Student > Ph. D. Student | 9 | 8% |
| Other | 22 | 18% |
| Unknown | 28 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
| Nursing and Health Professions | 6 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 9 | 8% |
| Unknown | 35 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2017.
All research outputs
#7,825,407
of 25,732,188 outputs
Outputs from Cardiovascular Diabetology
#596
of 1,688 outputs
Outputs of similar age
#115,099
of 334,635 outputs
Outputs of similar age from Cardiovascular Diabetology
#11
of 24 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,688 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,635 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.